ArticleCancer medicine2015

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

Diletta Fontana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.